Epidemiology and diagnosis of hypoparathyroidism

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 6, 2016, Pages 2284-2299

  Clarke, Bart L ^a   Brown, Edward M ^b   Collins, Michael T ^c   Jüppner, Harald ^d   Lakatos, Peter ^e   Levine, Michael A ^f   Mannstadt, Michael M ^d   Bilezikian, John P ^g   Romanischen, Anatoly F ^h   Thakker, Rajesh V ⁱ  

^a MAYO CLINIC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g Massachusetts General Hospital ^*  (United States)

^h SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRAIN CALCIFICATION; CLINICAL FEATURE; CLINICAL PRACTICE; COST OF ILLNESS; DISEASE ASSOCIATION; GENETIC SCREENING; HORMONE DETERMINATION; HOSPITALIZATION; HUMAN; HYPOPARATHYROIDISM; KIDNEY FAILURE; MORBIDITY; MORTALITY; NEPHROLITHIASIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PSEUDOHYPOPARATHYROIDISM; SUBCAPSULAR CATARACT; CATARACT; COMPLICATION; DENMARK; INCIDENCE; KIDNEY CALCULI; RENAL INSUFFICIENCY; RISK; UNITED STATES;

CATARACT; DENMARK; HUMANS; HYPOPARATHYROIDISM; INCIDENCE; KIDNEY CALCULI; PREVALENCE; RENAL INSUFFICIENCY; RISK; UNITED STATES;

EID: 84973542713     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3908     Document Type: Article

References (75)

1. Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26:2317-2337.
2. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359:391-403.
3. Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of hypoparathyroidism: Etiologies and clinical features. J Clin Endocrinol Metab. 2016;101:2300-2312.
4. Powers J, Joy K, Ruscio A, Lagast H. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013;28:2570-2576.
5. Clarke BL, Leibson C, Emerson J, Ransom JE, Lagast H. Co-morbid-medical conditions associated with prevalent hypoparathyroidism: A population-based study. J Bone Miner Res. 2011;26:S182 (Abstract SA1070).
6. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: A Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013;28:2277-2285.
7. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Postsurgical hypoparathyroidism-risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. 2014;29:2504-2510.
8. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. The epidemiology of nonsurgical hypoparathyroidism in Denmark: A nationwide case finding study. J Bone Miner Res. 2015;30:1738-1744.
9. Ito Y, Kihara M, Kobayashi K, Miya A, Miyauchi A. Permanent hypoparathyroidism after completion total thyroidectomy as a second surgery: how do we avoid it? Endocr J. 2014;61:403-408.
10. Romanchishen AF. The use of chromothyrolymphography for selection of surgical volume in patients with thyroid cancer. Voprosy Oncologii. 1989;35:1037-1040.
11. Romanchishen AF. Surgery of Thyroid and Parathyroid Glands. Saint Petersburg, Russia: Vesty; 2009.
12. Page C, Strunski V. Parathyroid risk in total thyroidectomy for bilateral, benign, multinodular goitre: Report of 351 surgical cases. J Laryngol Otol. 2007;121:237-241.
13. Asari R, Passler C, Kaczirek K, Scheuba C, Niederle B. Hypoparathyroidism after total thyroidectomy: A prospective study. Arch Surg. 2008;143:132-137; discussion 138.
14. Betterle C, Garelli S, Presotto F. Diagnosis and classification of autoimmune parathyroid disease. Autoimmun Rev. 2014;13:417-422.
15. Leibson C, Clarke BL, Ransom JE, Lagast H. Medical care costs for persons with and without prevalent hypoparathyroidism: A population-based study. J Bone Miner Res. 2011;26:S183 (Abstract SA1071).
16. Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012; 97:4507-4514.
17. Krause KH, Campbell KP, Welsh MJ, Lew DP. The calcium signal and neutrophil activation. Clin Biochem. 1990;23:159-166.
18. Illum F, Dupont E. Prevalences of CT-detected calcification in the basal ganglia in idiopathic hypoparathyroidism and pseudohypoparathyroidism. Neuroradiology. 1985;27:32-37.
19. Goswami R, Sharma R, Sreenivas V, Gupta N, Ganapathy A, Das S. Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism. Clin Endocrinol (Oxf). 2012;77:200-206.
20. Tambyah PA, Ong BK, Lee KO. Reversible parkinsonism and asymptomatic hypocalcemia with basal ganglia calcification from hypoparathyroidism 26 years after thyroid surgery. Am J Med. 1993;94:444-445.
21. Forman MB, Sandler MP, Danziger A, Kalk WJ. Basal ganglia calcification in postoperative hypoparathyroidism. Clin Endocrinol (Oxf). 1980;12:385-390.
22. Thakker RV, Bringhurst FR, Jüppner H. Regulation of calcium homeostasis and genetic disorders that affect calcium metabolism. In: De Groot LJ, Jameson JL, eds. Endocrinology. 7th ed. Philadelphia, PA: Elsevier; 2016:1063-1089.
23. Hannan FM, Thakker RV. Investigating hypocalcaemia. BMJ. 2013;346:2213.
24. Levine MA. An update on the clinical and molecular characteristics of pseudohypoparathyroidism. Curr Opin Endocrinol Diabetes Obes. 2012;19:443-451.
25. Bastepe M. Genetics and epigenetics of parathyroid hormone resistance. Endocr Dev. 2013;24:11-24.
26. Bastepe M, Jüppner H. Pseudohypoparathyroidism, Albright's hereditary osteodystrophy, and progressive osseous heteroplasia: disorders caused by inactivating GNAS mutations. In: Jameson JL, DeGroot LJ, eds. Endocrinology. 7th ed. Philadelphia, PA: Elsevier; 2016:1147-1159.
27. Neary NM, El-Maouche D, Hopkins R, Libutti SK, Moses AM, Weinstein LS. Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B. J Clin Endocrinol Metab. 2012;97:3025-3030.
28. Lee S, Mannstadt M, Guo J, et al. A homozygous [Cys25]PTH(1-84) mutation that impairs PTH/PTHrP receptor activation defines a novel form of hypoparathyroidism. J Bone Miner Res. 2015;30: 1803-1813.
29. Akin L, Kurtoǧ lu S, Yildiz A, Akin MA, Kendirici M. Vitamin D deficiency rickets mimicking pseudohypoparathyroidism. J Clin Res Pediatr Endocrinol. 2010;2:173-175.
30. Winer KK, Zhang B, Shrader JA, et al. Synthetic human parathyroid hormone 1-34 replacement therapy: A randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:391-399.
31. Linglart A, Menguy C, Couvineau A, et al. Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance.N Engl J Med. 2011;364:2218-2226.
32. Thiele S, de Sanctis L, Werner R, et al. Functional characterization of GNAS mutations found in patients with pseudohypoparathyroidism type Ic defines a new subgroup of pseudohypoparathyroidism affecting selectively Gs-α receptor interaction. Hum Mutat. 2011;32:653-660.
33. Michot C, Le Goff C, Goldenberg A, et al. Exome sequencing identifies PDE4D mutations as another cause of acrodysostosis. Am J Hum Genet. 2012;90:740-745.
34. Kaname T, Ki CS, Niikawa N, et al. Heterozygous mutations in cyclic AMP phosphodiesterase-4D (PDE4D) and protein kinase A (PKA) provide new insights into the molecular pathology of acrodysostosis. Cell Signal. 2014;26:2446-2459.
35. Mantovani G. Clinical review: pseudo hypoparathyroidism: diagnosis and treatment. J Clin Endocrinol Metab. 2011;96:3020-3030.
36. Molinaro A, Tiosano D, Takatani R, et al.TSH elevations as the first laboratory evidence for pseudohypoparathyroidism type Ib (PHPIb). J Bone Miner Res. 2015;30:906-912.
37. Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3570-3579.
38. D'Amour P. Acute and chronic regulation of circulating PTH: Significance in health and in disease. Clin Biochem. 2012;45:964-969.
39. Zhang CX, Weber BV, Thammavong J, Grover TA, Wells DS. Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at low-picomolar levels by mass spectrometry. Anal Chem. 2006;78:1636-1643.
40. Inaba M, Nakatsuka K, Imanishi Y, et al. Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem. 2004;50:385-390.
41. D'Amour P, Brossard JH, Räkel A, Rousseau L, Albert C, Cantor T. Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19. Clin Chem. 2005;51:169-176.
42. Grigorieva IV, Thakker RV. Transcription factors in parathyroid development: lessons from hypoparathyroid disorders. Ann NY Acad Sci. 2011;1237:24-38.
43. Ogata T, Niihori T, Tanaka N, et al. TBX1 mutation identified by exome sequencing in a Japanese family with 22q11.2 deletion syndrome-like craniofacial features and hypocalcemia. Plos one. 2014;9:e91598.
44. Naiki M, Ochi N, Kato YS, et al. Mutations in HADHB, which encodes the-α subunit of mitochondrial trifunctional protein, cause infantile onset hypoparathyroidism and peripheral polyneuropathy. Am J Med Genet. 2014;164A:1180-1187.
45. Jyonouchi S, McDonald-McGinn DM, Bale S, Zackai EH, Sullivan KE. CHARGE (coloboma, heart defect, atresia choanae, retarded growth and development, genital hypoplasia, ear anomalies/deafness) syndrome and chromosome 22q11.2 deletion syndrome: A comparison of immunologic and nonimmunologic phenotypic features. Pediatrics. 2009;123:e871-e877.
46. Hannan FM, Nesbit MA, Zhang C, et al. Identification of 70 calcium-sensing receptor mutations in hyper-and hypo-calcaemic patients: Evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum Mol Genet. 2012;21:2768-2778.
47. Nesbit MA, Hannan FM, Howles SA, et al. Mutations affecting G-protein subunit α 11 in hypercalcemia and hypocalcemia. N Engl J Med. 2013;368:2476-2486.
48. Mannstadt M, Harris M, Bravenboer B, et al. Germline mutations affecting G-11 in hypoparathyroidism. N Engl J Med. 2013;368: 2532-2534.
49. Li D, Opas EE, Tuluc F, et al. Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization. J Clin Endocrinol Metab. 2014;99: E1774-E1783.
50. Taylor JC, Martin HC, Lise S, et al. Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nat Genet. 2015;47:717-726.
51. Chillambhi S, Turan S, Hwang DY, Chen HC, Jüppner H, Bastepe M. Deletion of the noncoding GNAS antisense transcript causes pseudohypoparathyroidism type Ib and biparental defects of GNAS methylation in cis. J Clin Endocrinol Metab. 2010;95:3993-4002.
52. Richard N, Abeguilé G, Coudray N, et al. A new deletion ablating NESP55 causes loss of maternal imprint of A/B GNAS and autosomal dominant pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab. 2012;97:E863-E867.
53. Elli FM, de Sanctis L, Peverelli E, et al. Autosomal dominant pseudohypoparathyroidism type Ib: A novel inherited deletion ablating STX16 causes loss of imprinting at the A/B DMR. J Clin Endocrinol Metab. 2014;99:E724-E728.
54. Weinstein LS, Xie T, Qasem A, Wang J, Chen M. The role of GNAS and other imprinted genes in the development of obesity. Int J Obes (Lond). 2010;34:6-17.
55. Lemos MC, Thakker RV. GNAS mutations in pseudohypoparathyroidism type 1a and related disorders. Hum Mut. 2015;36:11-19.
56. Mouallem M, Shaharabany M, Weintrob N, et al. Cognitive impairment is prevalent in pseudohypoparathyroidism type Ia, but not in pseudopseudohypoparathyroidism: possible cerebral imprinting of Gsα. Clin Endocrinol (Oxf). 2008;68:233-239.
57. Al-Salameh A, Despert F, Kottler ML, Linglart A, Carel JC, Lecomte P. Resistance to epinephrine and hypersensitivity (hyperresponsiveness) to CB1 antagonists in a patient with pseudohypoparathyroidism type Ic. Eur J Endocrinol. 2010;162:819-824.
58. Dekelbab BH, Aughton DJ, Levine MA. Pseudohypoparathyroid-ism type 1A and morbid obesity in infancy. Endocr Pract. 2009;15: 249-253.
59. Lebrun M, Richard N, Abeguilé G, et al. Progressive osseous heteroplasia: A model for the imprinting effects of GNAS inactivating mutations in humans. J Clin Endocrinol Metab. 2010;95:3028-3038.
60. Pignolo RJ, Ramaswamy G, Fong JT, Shore EM, Kaplan FS. Progressive osseous heteroplasia: diagnosis, treatment, and prognosis. Appl Clin Genet. 2015;8:37-48.
61. Regard JB, Malhotra D, Gvozdenovic-Jeremic J, et al. Activation of hedgehog signaling by loss of GNAS causes heterotopic ossification. Nat Med. 2013;19:1505-1512.
62. Richard N, Molin A, Coudray N, Rault-Guillaume P, Jüppner H, Kottler ML. Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLαs in fetal development. J Clin Endocrinol Metab. 2013;98:E1549-E1556.
63. Lau K, Willig RP, Hiort O, Hoeger PH. Linear skin atrophy preceding calcinosis cutis in pseudo-pseudohypoparathyroidism. Clin Exp Dermatol. 2012;37:646-648.
64. Martin J, Tucker M, Browning JC. Infantile osteoma cutis as a presentation of a GNAS mutation. Pediatr Dermatol. 2012;29:483-484.
65. Ward S, Sugo E, Verge CF, Wargon O. Three cases of osteoma cutis occurring in infancy. A brief overview of osteoma cutis and its association with pseudo-pseudohypoparathyroidism. Australas J Dermatol. 2011;52:127-131.
66. Adegbite NS, Xu M, Kaplan FS, Shore EM, Pignolo RJ. Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification.AmJ Med Genet A. 2008;146A:1788-1796.
67. Thakker RV. The parathyroid glands, hypercalcemia, and hypocalcemia. In: Goldman L, Shafer AI, eds. Goldman-Cecil Medicine. 25th ed. Atlanta, GA: Elsevier Ltd; 2016:1649-1661.
68. Sanchez J, Perera E, Jan de Beur S, et al. Madelung-like deformity in pseudohypoparathyroidism type 1b. J Clin Endocrinol Metab. 2011;96:E1507-E1511.
69. Turan S, Ignatius J, Moilanen JS, et al. De novo STX16 deletions: An infrequent cause of pseudohypoparathyroidism type Ib that should be excluded in sporadic cases. J Clin Endocrinol Metab. 2012;97: E2314-E2319.
70. Xie T, Plagge A, Gavrilova O, et al. The alternative stimulatory G protein α subunit XL-s is a critical regulator of energy and glucose metabolism and sympathetic nerve activity in adult mice. J Biol Chem. 2006;281:18989-18999.
71. Bastepe M, Altug-Teber O, Agarwal C, Oberfield SE, Bonin M, Jüppner H. Paternal uniparental isodisomy of the entire chromosome 20 as a molecular cause of pseudohypoparathyroidism type Ib (PHP-Ib). Bone. 2011;48:659-662.
72. Fernández-Rebollo E, Lecumberri B, Garin I, et al.Newmechanisms involved in paternal 20q disomy associated with pseudohypoparathyroidism. Eur J Endocrinol. 2010;163:953-962.
73. Takatani R, Minagawa M, Molinaro A, et al. Similar frequency of paternal uniparental disomy involving chromosome 20q (patUPD20q) in Japanese and Caucasian patients affected by sporadic pseudohypoparathyroidism type Ib (sporPHP1B). Bone. 2015;79:15-20.
74. Jin HY, Lee BH, Choi JH, et al. Clinical characterization and identification of two novel mutations of the GNAS gene in patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism. Clin Endocrinol (Oxf). 2011;75:207-213.
75. Mitsui T, Narumi S, Inokuchi M, et al. Comprehensive next-generation sequencing analyses of hypoparathyroidism: identification of novel GCM2 mutations. J Clin Endocrinol Metab. 2014;99: E2421-E2428.